Amyotrophic Lateral Sclerosis (ALS)

Misfolded SOD1 Found in Sporadic ALS Samples

A new study suggests misfolding of the SOD1 protein may be a common contributor not only to familial (inherited) amyotrophic lateral sclerosis (ALS) caused by mutations in the SOD1 gene but to the more common sporadic (noninherited) form of the disease as well.

ALS TDI Conference Summarizes ALS Research Progress

Themes discussed throughout the research symposium included ALS genetics, clinical trials, the role of the immune system in disease onset and progression, biomarkers, and the use of stem cells in ALS therapeutics.

Diaphragm Pacing System Awaiting FDA Approval for ALS

The Synapse Biomedical NeuRx Diaphragm Pacing System (DPS), a device that stimulates the respiratory diaphragm with electrical signals, has received Humanitarian Use Device designation from the U.S. Food and Drug Administration (FDA), allowing it to be used by people with amyotrophic lateral sclerosis (ALS) who have a “stimulatable” diaphragm and are experiencing chronic breathing problems.

MDA/ALS Research Center Earns Prestigious Award

The Forbes Norris MDA/ALS Research and Treatment Center in San Francisco has received Program of the Year honors from the California Speech-Language-Hearing Association (CSHA).

ALS Research Briefs

Trial results announced for drug for laughing/crying jags

Deshae Lott Scholarships Awarded

Three accomplished scholars determinedly pursuing their educations while living with neuromuscular disease are the first winners of the CMMS Deshae Lott Ministries outreach program scholarships.

Deshae Lott Scholarships Awarded

Three accomplished scholars determinedly pursuing their educations while living with neuromuscular disease are the first winners of the CMMS Deshae Lott Ministries outreach program scholarships.

“We were so impressed,” with the winning candidates, said Deshae Lott, 39, a teacher and minster from Bossier City, La., who founded the nonprofit that bears her name. “These three show great strength of mind and character. Each of them strives to maximize within their limitations.”

ALS Research Briefs

DNA variants

Variant sequences of DNA within a small region of chromosome 9 have been found to be associated with sporadic ALS (ALS without a family history) in a study that compared samples from people with and without the disease living in the United Kingdom, United States, Netherlands, Ireland, Italy, France, Sweden and Belgium; and in another study that compared DNA samples from those with familial ALS (ALS with a family history) to those without the disease in Finland.

See:

Learn More About Ceftriaxone and ALS

Editor's note: The information on joining this webinar has been updated, per the presenters, Sept. 1, 2010.

A clinical trial of the drug ceftriaxone in amyotrophic lateral sclerosis (ALS) is currently recruiting participants at 54 locations across the United States and Canada. (For details, see Ceftriaxone Trial Still Open.) Laboratory studies suggest the drug protects motor neurons from injury.

ALS Research Briefs

Biogen Idec and Knopp Neurosciences announced Aug. 18, 2010, that they have entered into an agreement to continue developing KNS-760704 (dexpramipexole) as an experimental treatment for ALS. The drug helps protect nerve cells under adverse conditions. A phase 2 trial by Knopp showed the drug had favorable effects on motor function and survival in people with ALS.

Pages